In honor of Rare Disease Day, we discuss news from Healx, a clinical-stage biotech, which has dosed the first patient in a Phase II trial of its new drug for neurofibromatosis type 1. In the world of AI, the Arc Institute in collaboration with Nvidia has dropped Evo 2, the “largest publicly accessible AI model for biology to date,” for designing genomes. Additionally, new work from Nobel Laureate, David Baker, uses AI to generate enzymes from scratch. We also dig into the big announcements from Illumina and Roche that got the community buzzing ahead of this year’s AGBT meeting.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options
By Alex Philippidis, GEN Edge, February 25, 2025
Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life
By Fay Lin, PhD, GEN Edge, February 19, 2025
AI-Driven Protein Design Produces Enzyme that Mimics Natural Hydrolase Activity
By Corinna Singleman, PhD, GEN, February 13, 2025
Illumina Unveils Spatial Technology Days Before AGBT Meeting
By Julianna LeMieux, PhD, GEN, February 19, 2025
StockWatch: Illumina Tumbles on Q4 Results, China Retaliation
By Alex Philippidis, GEN Edge, February 8, 2025
Roche Announces SBX Technology, Creates Sequencing Buzz
By Julianna LeMieux, PhD, GEN, February 21, 2025
StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks
By Alex Philippidis, GEN Edge, February 17, 2025
